RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Authors
Yoon, H.Kato, K.
Raymond, E.
Hubner, Richard A
Shu, Y.
Pan, Y.
Jiang, Y.
Zhang, J.
Park, S.
Kojima, T.
Lin, C.
Gotovkin, E.
Wyrwicz, L.
Ishihara, R.
Li, L.
Tao, A.
Shi, J.
Wang, L.
Xu, J.
Affiliation
Mayo Clinic, Rochester, United StatesIssue Date
2022